


## COX-2-IN-24

Cat. No.:	HY-147963
CAS No.:	2417995-10-7
Molecular Formula:	C <sub>24</sub> H <sub>24</sub> BrN <sub>5</sub> O <sub>3</sub> S <sub>2</sub>
Molecular Weight:	574.51
Target:	COX
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	COX-2-IN-24 is an orally active inhibitor of COX-2 with IC <sub>50</sub> value of 0.17 μM, shows anti-inflammatory and low ulcerogenic activities.																
<b>IC<sub>50</sub> &amp; Target</b>	COX-2 0.17 μM (IC <sub>50</sub> )																
<b>In Vivo</b>	<p>COX-2-IN-24 (Intraperitoneal injection; 9mg/100g; once an hour; 4 hours) shows anti-inflammatory activity in the carrageenan-induced rat paw edema model<sup>[1]</sup>.</p> <p>COX-2-IN-24 (Oral gavage; 9mg/100g; once a day; 3 days) shows low ulcerogenic activity in the received 1% gum acacia (suspending vehicle) orally male albino rats model<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Mature male albino rats<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>9mg/100g</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 9mg/100g; once an hour; 4 hours</td> </tr> <tr> <td>Result:</td> <td>Exhibited a promising anti-inflammatory activity in the carrageenan-induced rat paw edema model.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Mature male albino rats<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>9mg/100g</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage; 9mg/100g; once a day; 3 days</td> </tr> <tr> <td>Result:</td> <td>Exhibited low ulcerogenic activity in the received 1% gum acacia (suspending vehicle) orally male albino rats model.</td> </tr> </table>	Animal Model:	Mature male albino rats <sup>[1]</sup>	Dosage:	9mg/100g	Administration:	Intraperitoneal injection; 9mg/100g; once an hour; 4 hours	Result:	Exhibited a promising anti-inflammatory activity in the carrageenan-induced rat paw edema model.	Animal Model:	Mature male albino rats <sup>[1]</sup>	Dosage:	9mg/100g	Administration:	Oral gavage; 9mg/100g; once a day; 3 days	Result:	Exhibited low ulcerogenic activity in the received 1% gum acacia (suspending vehicle) orally male albino rats model.
Animal Model:	Mature male albino rats <sup>[1]</sup>																
Dosage:	9mg/100g																
Administration:	Intraperitoneal injection; 9mg/100g; once an hour; 4 hours																
Result:	Exhibited a promising anti-inflammatory activity in the carrageenan-induced rat paw edema model.																
Animal Model:	Mature male albino rats <sup>[1]</sup>																
Dosage:	9mg/100g																
Administration:	Oral gavage; 9mg/100g; once a day; 3 days																
Result:	Exhibited low ulcerogenic activity in the received 1% gum acacia (suspending vehicle) orally male albino rats model.																

### REFERENCES

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA